ITIL-306 is under clinical development by Instil Bio and currently in Phase I for Lung Adenocarcinoma. According to GlobalData, Phase I drugs for Lung Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ITIL-306 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ITIL-306 is under development for the treatment of gynecological cancers, non-small cell lung cancer, epithelial ovarian cancer, high grade serous, endometrioid, or clear cell epithelial carcinoma of fallopian tube, or peritoneum, lung adenocarcinoma, papillary renal cell carcinoma and solid tumors. The therapeutic candidate comprises tumor infiltrating lymphocytes (TIL) genetically engineered to express a Co-Stimulatory Antigen Receptor (CoStAR) molecule targeting folate receptor alpha (FOLR1). It is administered through parenteral route.
Instil Bio overview
Instil Bio is a biopharmaceutical company that develops optimized and genetically-engineered tumor infiltrating lymphocytes (TIL) for the treatment of cancer. It is investigating its lead product candidate ITIL-168 against melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. The company is also offers ITIL-306 drug to treat gynaecological malignancies among other. Instil Bio utilizes its proprietary TIL manufacturing platform to develop its products. The company operates research and cell therapy manufacturing facilities in Los Angeles, the US and Manchester, the UK. Instil Bio is headquartered in Dallas, Texas, the US.
For a complete picture of ITIL-306’s drug-specific PTSR and LoA scores, buy the report here.